Novavax Readies COVID-19 Vaccine for FDA Advisory Committee Meeting

Plagued by a slow rollout of its COVID-19 vaccine overseas, Maryland-based Novavax is seeing a ray of sunshine in the United States. The U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee is set to review clinical data on June 7 and potentially suggest approval of NVX-CoV2373, a recombinant, adjuvanted COVID-19 vaccine currently marketed overseas as Nuvaxovid.